ArticleMedChemComm2018
Saponin from sea cucumber exhibited more significant effects than ginsenoside on ameliorating high fat diet-induced obesity in C57BL/6 mice.
Article in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Untargeted UHPLC-MS/MS analysis of intestines of high-valueFood chemistry: X · 2026Article
- Article
- Natural products in atherosclerosis therapy by targeting PPARs: a review focusing on lipid metabolism and inflammation.Frontiers in cardiovascular medicine · 2024Review
- A study on the treatment effects ofFrontiers in veterinary science · 2024Article
- A Comprehensive Review of Phytonutrients as a Dietary Therapy for Obesity.Foods (Basel, Switzerland) · 2023Review
- Inhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways.Metabolites · 2023Review
- Sea Cucumber Saponins Derivatives Alleviate Hepatic Lipid Accumulation Effectively in Fatty Acids-Induced HepG2 Cells and Orotic Acid-Induced Rats.Marine drugs · 2022Article
- A Comparative Study of the Anti-Obesity Effects of Dietary Sea Cucumber Saponins and Energy Restriction in Response to Weight Loss and Weight Regain in Mice.Marine drugs · 2022Article
- Sea cucumber-derived compounds for treatment of dyslipidemia: A review.Frontiers in pharmacology · 2022Review
- Marine Natural Products and Coronary Artery Disease.Frontiers in cardiovascular medicine · 2021Review
- Characterization of a Coproduct from the Sea CucumberMarine drugs · 2020Article
- Advances in the Study of Marine Products with Lipid-Lowering Properties.Marine drugs · 2020Review
- Relationship Between Ginsenoside Rg3 and Metabolic Syndrome.Frontiers in pharmacology · 2020Review
- Consumption of Cooked Common Beans or Saponins Could Reduce the Risk of Diabetic Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and its comorbidities are considered to be a severe public health problem. Many natural compounds found in food have been proved to ameliorate the metabolic abnormalities induced by obesity. The purpose of this study was to compare the effects of saponin from sea cucumber (SSC) and ginsenoside (SG) on improving the lipid metabolism in C57BL/6 mice fed with a high fat diet. The mice were randomly divided into six groups including a low fat diet group (LF), a high fat diet group (HF), and four dietary intervention groups. The administration of SSC for 8 weeks exhibited a more significant reduction in HF induced fat mass, weight gain, lipid levels in the liver and serum, and serum glucose and insulin levels than SG. Further research indicated that SSC ameliorated high fat diet-induced obesity in C57BL/6 mice mainly through inhibiting lipid synthesis and accelerating lipid β-oxidation and glycolysis in the liver. These results suggested that saponin from sea cucumber might be applied as a food supplement and/or functional ingredient to relieve metabolic disorders induced by obesity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.